Provention Bio

Provention Bio ROE

Delisted

The Return on Equity (ROE) of Provention Bio (PRVB) as of Oct 26, 2026 is -93.20 %. In the previous year, Return on Equity (ROE) was 39.18 % — a change of -337.89% (lower).

ROE

-93.20 %

YoY

-337.89%

Last updated:

In 2022, Provention Bio's return on equity (ROE) was -93.20 %, a -337.89% increase from the 39.18 % ROE in the previous year.

The Provention Bio ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2016
100.00 USD
Jan 1, 2017
-45.32 USD
Jan 1, 2018
-44.38 USD
Jan 1, 2019
53.37 USD
Jan 1, 2020
55.49 USD
Jan 1, 2021
39.18 USD
Jan 1, 2022
-93.20 USD
The Provention Bio ROE history
YEARROEYoY
-93.20 %-337.89%
39.18 %-29.40%
55.49 %+3.97%
53.37 %-220.26%
-44.38 %-2.07%
-45.32 %-145.32%
100.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Provention Bio Stock analysis

What does Provention Bio do? Provention Bio Inc is a US biotechnology company specializing in the development of preventive therapies for autoimmune diseases and other chronic conditions. The company was founded in 2016 by a group of experienced biotech managers and has its headquarters in Oldwick, New Jersey. The history of Provention Bio begins with the recognition that many current treatments for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus only aim to treat the symptoms of the disease rather than addressing their causes. Therefore, the company is committed to developing innovative and preventive therapies that directly target the causes of autoimmune diseases. Provention Bio's business model is based on sourcing and developing new therapies through to commercialization. The company is dedicated to early-stage research and development and works closely with academic institutions, government agencies, and other companies to achieve its goals. Additionally, Provention Bio invests in clinical trials to prove the efficacy of its therapies and ensure their approval by regulatory authorities. The various divisions of Provention Bio encompass some of the most important autoimmune diseases currently lacking effective cures. These include type 1 diabetes, celiac disease, lupus, MS, and other rare autoinflammatory diseases. Provention Bio's products aim to regulate the immune system and enhance the body's self-healing by influencing biological processes. One of Provention Bio's key products is Teplizumab, a preventive medication for the treatment of type 1 diabetes. The company has acquired the exclusive global rights to this medication, relying on promising results from its clinical trials. Since its FDA approval in 2021, the medication has filled an important market need. Additionally, Provention Bio has several other potential therapies in its pipeline. Among them is PRV-3279, a medication specifically developed for the treatment of celiac disease, currently in phase 2 clinical trials. Additionally, Teplizumab is being investigated for use in other autoimmune diseases such as lupus and MS. The goal of Provention Bio is to positively impact the quality of life and health of millions of people worldwide. The company is working hard to develop innovative preventive therapy approaches that focus on the causes of autoimmune diseases rather than just treating the symptoms. In doing so, Provention Bio is a significant addition to the wide range of existing treatment options by significantly expanding therapeutic choices. In summary, Provention Bio Inc is considered an emerging biotechnology company with great potential in the preventive treatment of autoimmune diseases. The company has a promising pipeline of therapies that have the potential to improve the lives of millions of people worldwide. The company aims to develop preventive and effective therapies that directly address the causes of autoimmune diseases. Provention Bio is one of the most popular companies on Eulerpool.

ROE Details

Decoding Provention Bio's Return on Equity (ROE)

Provention Bio's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Provention Bio's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Provention Bio's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Provention Bio’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Provention Bio stock

Return on Equity (ROE) of Provention Bio is -93.20 % in 2022.

Return on Equity (ROE) of Provention Bio changed from 39.18 % to -93.20 %, representing a -337.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Provention Bio since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Provention Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Provention Bio

All Key Metrics — Provention Bio